PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis. Combining AI with their patented Morphology Feature Array® (MFA), PreciseDx provides highly accurate, actionable intelligence and disease insights that support better decision-making throughout the cancer care continuum.


  • Increase awareness and visibility of PreciseDx
  • Drive thought leadership through subject matter expert’s POV on key industry topics: AI in healthcare, pathology/oncology innovation, etc
  • Communicate scientifically-proven superiority over the standard of care and deliver key product messages, highlighting accuracy, timeliness, and cost-effectiveness
  • Promote PreciseBreast™ as the new standard in assessing cancer risk of recurrence

2023 Results

including: Fierce Healthcare, Fierce Biotech, Fierce Pharma, The Pathologist, WSJ Venture Capital, Forbes, Precision Medicine Online, Healthcare IT News, BioWorld MedTech, Clinical Lab Products, 360Dx, BioSpace, and Lab Pulse, among others

media impressions


media interviews to
build relationships


byline articles highlighting
thought leadership


Social media impressions


grew LinkedIn account
from 418 followers to


Website & Collateral

Group 28864
Group 28866
Group 28862
Group 28865
Group 28854
Group 28861

Media Highlights

Group 28847
Group 28856
Group 28846
Group 28860
Group 28868
Group 28867